7712 Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 

understand needed improvements in 

these systems. 

The NHSS would classify HIV 

infections as Stage 0 if the first positive 

HIV test were within six months of a 

negative HIV test. Persons who received 

a diagnosis at Stage 0 (i.e., early 

diagnosis) could access HIV testing 

shortly after infection yet could not 

benefit from biomedical and behavioral 

interventions to prevent HIV infection. 

The federal Ending the HIV Epidemic in 

the U.S. (EHE) initiative prioritizes the 

provision of HIV preexposure 

prophylaxis (PrEP), syringe services 

programs, treatment as prevention 

efforts, and other proven 

interventions—as part of the Prevent 

pillar of the EHE initiative—to prevent 

new HIV infections. 

HIV infections are classified as Stage 

3 (AIDS) by the presence of an AIDSdefining opportunistic infection or by 

the lowest CD4 lymphocyte test result. 

Persons with Stage 3 infection at the 

time of their initial HIV diagnosis (i.e., 

late diagnosis) did not benefit from 

timely receipt of testing or HIV 

prevention interventions. They were 

likely unaware of their infection for a 

substantial length of time. 

Nationally, an estimated 13.3% of 

persons with HIV are unaware of their 

infection, contributing to an estimated 

40% of all ongoing transmission. 

Increasing early diagnosis is a crucial 

pillar of efforts to end HIV in the United 

States. Given the continued occurrence 

of HIV infections in the United States, 

the barriers and gaps associated with 

low uptake of HIV testing and 

prevention services must be addressed 

to reduce new infections and facilitate 

timely diagnosis and treatment. 

Individual- and systems-level factors 

likely contribute to barriers and gaps in 

testing and prevention. Therefore, CDC 

is sponsoring this data collection to 

improve understanding of barriers and 

gaps associated with new infection and 

late diagnosis in the era of multiple 

testing modalities and prevention 

options such as PrEP. These enhanced 

surveillance activities will identify 

actionable missed opportunities for 

early diagnosis and prevention, thus 

informing allocation of resources, 

development and prioritization of 

interventions, and evidence-based local 

and national decisions to improve HIV 

testing and address prevention gaps. 

The changes proposed in this request 

add a new qualitative data collection 

activity that encompasses a new consent 

form and a new data collection tool (Indepth Interview Guide) to conduct 

qualitative interviews to meet prevailing 

information needs and enhance the 

value of SHIELD data and minor edits 

to the approved SHIELD survey while 

remaining within the scope of the 

currently approved project purpose. The 

annualized burden hours of the project 

increased by 158 hours with these 

additions, for a total of 3,074 annualized 

burden hours. There are no costs to 

respondents other than time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Potential Eligible Participant ................... Recruitment Script English ..................................... 2,000 1 15/60 

Potential Eligible Participant ................... Recruitment Script Spanish .................................... 500 1 15/60 

Eligible Participant .................................. Consent for quantitative survey—English .............. 2,000 1 5/60 

Eligible Participant .................................. Consent—Spanish .................................................. 500 1 5/60 

Eligible Participant .................................. Survey—English ..................................................... 2,000 1 50/60 

Eligible Participant .................................. Survey—Spanish .................................................... 500 1 50/60 

Eligible Participant .................................. Consent for qualitative interview—English ............. 50 1 5/60 

Eligible Participant .................................. Consent for qualitative interview—Spanish ............ 50 1 5/60 

Eligible Participant .................................. In-depth Interview—English .................................... 50 1 90/60 

Eligible Participant .................................. In-depth Interview—Spanish ................................... 50 1 90/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–02172 Filed 2–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–0199; Docket No. CDC–2024– 

0008] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Import Permit. 

The goal of the information collection is 

to support the Public Health Service 

(PHS) Act and prevent the introduction, 

transmission, or spread of 

communicable diseases from foreign 

countries into the States or possessions, 

or from one State or possession into any 

other State or possession. 

DATES: CDC must receive written 

comments on or before April 5, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0008 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 7713 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Import Permit Applicatons (42 CFR 

71.54) (OMB Control No. 0920–0199, 

Exp. 8/31/2024)—Revision—Office of 

Readiness and Response (ORR), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

Section 361 of the Public Health 

Service Act (42 U.S.C. 264), as 

amended, authorizes the Secretary of 

Health and Human Services to make 

and enforce such regulations as are 

necessary to prevent the introduction, 

transmission, or spread of 

communicable diseases from foreign 

countries into the States or possessions, 

or from one State or possession into any 

other State or possession. Part 71 of 

Title 42, Code of Federal Regulations 

(Foreign Quarantine) sets forth 

provisions to prevent the introduction, 

transmission, and spread of 

communicable disease from foreign 

countries into the United States. 

Subpart F—Importations—contains 

provisions for the importation of 

infectious biological agents, infectious 

substances, and vectors (42 CFR 71.54); 

requiring persons that import these 

materials to obtain a permit issued by 

the CDC. The Application for Permit to 

Import Biological Agents, Infectious 

Substances and Vectors of Human 

Disease into the United States form is 

used by laboratory facilities, such as 

those operated by government agencies, 

universities, and research institutions to 

request a permit for the importation of 

biological agents, infectious substances, 

or vectors of human disease. This form 

currently requests applicant and sender 

contact information; description of 

material for importation; facility 

isolation and containment information; 

and personnel qualifications. Based on 

questions we have received from prior 

applicants, CDC is proposing to reduce 

open text questions and replace them 

with more streamlined check boxes. The 

goal is that this will clarify what is 

being asked of applicants and will 

increase efficiency and speed of 

processing by reducing back and forth 

communication necessary to clarify to 

applicants. 

The Application for Permit to Import 

or Transport Live Bats form is used by 

laboratory facilities such as those 

operated by government agencies, 

universities, research institutions, and 

for educational, exhibition, or scientific 

purposes to request a permit for the 

importation, and any subsequent 

distribution after importation, of live 

bats. This form currently requests the 

applicant and sender contact 

information; a description and intended 

use of bats to be imported; and facility 

isolation and containment information. 

CDC does not plan to revise this 

application. 

The Application for Permit to Import 

Infectious Human Remains into the 

United States is used by facilities that 

will bury/cremate the imported cadaver 

and educational facilities to request a 

permit for the importation and 

subsequent transfers throughout the 

U.S. of human remains or body parts 

that contains biological agents, 

infectious substances, or vectors of 

human disease. This form will request 

applicant and sender contact 

information; facility processing human 

remains; cause of death; biosafety and 

containment information; and final 

destination(s) of imported infectious 

human remains. CDC does not plan to 

revise this application. 

The Importer Certification Statement 

is a new form and will be used as an 

attestation by an importer stating that 

they are importing only noninfectious 

biological agent(s) or biological 

substance(s). The noninfectious, 

imported agent or substance must be 

accompanied by an importer 

certification statement confirming that 

the material is not known to contain or 

suspected of containing an infectious 

biological agent or has been rendered 

noninfectious. This form requests a 

detailed description of the material, 

statements affirming that the material is 

not known or suspected to contain an 

infectious biological agent, and one of 

the following: (1) How the person 

knows that the material does not 

contain an infectious biological agent; 

(2) Why there is no reason to suspect 

that the material contains an infectious 

biological agent; or (3) A detailed 

description of how the material was 

rendered noninfectious. 

Annualized burden hours were 

calculated based on data obtained from 

CDC import permit database on the 

number of permits issued on annual 

basis since 2015, which is 2,000 

respondents. The total estimated burden 

for the data collection is 2,097. There is 

an increase in burden from 1,097 hours 

to 2,097 hours which reflects the new, 

proposed form (Importer Certification 

Statement), to this project. 


lotter on DSK11XQN23PROD with NOTICES1
7714 Federal Register / Vol. 89, No. 24 / Monday, February 5, 2024 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Applicants Requesting to Import Biological Agents, Infectious Substances and 

Vectors.

Application for Permit to Import Biological Agents, Infectious Substances and 

Vectors of Human Disease into the 

United States.

2,000 1 30/60 1,000 

Applicants Requesting to Import Biological Agents, Infectious Substances and 

Vectors.

Application for Permit to Import Biological Agents, Infectious Substances and 

Vectors of Human Disease into the 

United States Subsequent Transfer.

380 1 10/60 63 

Applicants Requesting to Import Live 

Bats.

Application for a Permit to Import Live 

Bats.

3 1 20/60 1 

Applicants Requesting to Import Infectious Human Remains into the United 

States.

Application for Permit to Import Infectious Human Remains into the United 

States.

100 1 20/60 33 

Importers of Non-infectious Materials to 

the United States.

Importer Certification Statement ............. 2,000 1 30/60 1,000 

Total .................................................. .................................................................. .................... ........................ .................... 2,097 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–02173 Filed 2–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Lead Exposure and Prevention 

Advisory Committee (LEPAC); Notice 

of Charter Renewal 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of charter renewal. 

SUMMARY: This gives notice under the 

Federal Advisory Committee Act of 

October 6, 1972, that the Lead Exposure 

and Prevention Advisory Committee 

(LEPAC), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services, has been renewed 

for a 2-year period through January 17, 

2026. 

FOR FURTHER INFORMATION CONTACT: Paul 

Allwood, Ph.D., MPH, Designated 

Federal Officer, National Center for 

Environmental Health, Centers for 

Disease Control and Prevention, 

Department of Health and Human 

Services, 1600 Clifton Road NE, MS 

S106–5, Atlanta, Georgia 30329–4018. 

Telephone (770) 488–6774; PAllwood@

cdc.gov. 

SUPPLEMENTARY INFORMATION: CDC is 

providing notice under 5 U.S.C. 1001– 

1014 of the renewal of the charter of the 

Lead Exposure and Prevention Advisory 

Committee, Centers for Disease Control 

and Prevention, Department of Health 

and Human Services. This charter has 

been renewed for a two-year period 

through January 17, 2026. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–02179 Filed 2–2–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0009; NIOSH–278] 

Meeting of the Board of Scientific 

Counselors, National Institute for 

Occupational Safety and Health 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting of the Board of 

Scientific Counselors, National Institute 

for Occupational Safety and Health 

(BSC, NIOSH). This is a virtual meeting. 

It is open to the public, limited only by 

the number of web conference lines (500 

lines are available). Time will be 

available for public comment. 

DATES: The meeting will be held on 

March 13, 2024, from 10 a.m. to 3:30 

p.m., EDT. 

Written comments must be received 

on or before March 6, 2024. 

ADDRESSES: If you wish to attend the 

meeting, please register at the NIOSH 

website at https://www.cdc.gov/niosh/ 

bsc/ or by telephone at (202) 245–0649 

no later than March 6, 2024. 

You may submit comments, identified 

by Docket No. CDC–2024–0009; 

NIOSH–278, by either of the methods 

listed below. CDC does not accept 

comments by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Ms. Sherri Diana, NIOSH 

Docket Office, National Institute for 

Occupational Safety and Health, 1090 

Tusculum Avenue, Mailstop C–34, 

Cincinnati, Ohio 45226. Attn: Docket 

No. CDC–2024–0009; NIOSH–278. 

Instructions: All submissions received 

must include the Agency name and 

docket number. Docket number CDC– 

2024–0009; NIOSH–278 will close 

March 6, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Maria Strickland, M.P.H., Designated 

Federal Officer, Board of Scientific 


lotter on DSK11XQN23PROD with NOTICES1